|
|
Post by sayhey24 on Mar 10, 2024 10:11:13 GMT -5
I googled it, The cost of a family restaurant meal. Unlock your healthiest body yet Promo: $99 first month, $145/month thereafter Semaglutide injection Semaglutide Medication (GLP-1) ro.co/weight-loss/semaglutide/#OK - there is our price point for Saxenda DPI. $99 a month or less. Can we make a profit selling Saxenda DPI through Weight Watchers and CostPlusDrugs for $99 or even $59? |
|
|
|
Post by sayhey24 on Mar 10, 2024 10:16:54 GMT -5
This explains the industry. The commercials are a payoff to the networks to keep their news people from covering the industry and exposing just how "dangerous" some of these drugs are. Years ago I was walking the "Freedom Trail" in Boston and one thing hit me. Along the trail are a lot of little cemeteries. When I started looking at the headstones I found it very interesting how many of these people lived into their 80's. How was that possible? They didn't have all these drugs and they didn't have Obamacare yet they lived pretty long lives. The 2023 life expectancy for a U.S. white male was 75. The only explanation I could come up with was they didn't smoke cigarettes and they drank lots of whiskey. tuckercarlson.com/the-case-against-ozempic/ You don't think maybe it's because those families that could afford the front row seats in the cemetery and big headstones had somewhat cushier lives? There are not many big headstones. There are a bunch of little cemeteries and I would say there are any front row seats. Its an interesting walk. Nope - I am sticking with the fact they drank a lot of whiskey. Back then they didn't buy it by the bottle but rather the barrel. |
|
|
|
Post by prcgorman2 on Mar 10, 2024 10:37:43 GMT -5
The #1 agricultural product of the colonies was tobacco. Cigarettes hadn’t been invented yet.
|
|
|
|
Post by stockwhisperer on Apr 5, 2024 6:33:00 GMT -5
Notice of Annual Shareholders Meeting, Wednesday, May 15, 2024…. www.streetinsider.com/dr/news.php?id=23032139&gfv=1Dear Stockholder: You are cordially invited to attend the Annual Meeting of Stockholders of MannKind Corporation, a Delaware corporation (“MannKind”). The meeting will be held live via the Internet on Wednesday, May 15, 2024 at 10:00 a.m. U.S. Eastern Time. To attend, please visit www.virtualshareholdermeeting.com/MNKD2024. You will not be able to attend the Annual Meeting in person. The Annual Meeting will consider the following matters: 1. To elect the nine nominees named herein as directors to serve for the ensuing year and until their successors are elected; 2. To approve, on an advisory basis, the compensation of the named executive officers of MannKind, as disclosed in MannKind’s proxy statement for the Annual Meeting; 3. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of MannKind for its fiscal year ending December 31, 2024; and 4. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. These items of business are more fully described in the proxy statement accompanying this notice. The record date for the Annual Meeting is March 18, 2024. Only stockholders of record on that date may vote at the meeting or any adjournment thereof. By Order of the Board of Directors img30985660_3.jpg David B. Thomson Executive Vice President, General Counsel and Secretary Danbury, Connecticut April 5, 2024 You are cordially invited to attend the meeting via the Internet. Whether or not you expect to attend the meeting, please vote by proxy pursuant to the instructions set forth herein as promptly as possible in order to ensure your representation at the meeting. Even if you have voted by proxy, you may still vote live if you attend the meeting via the Internet. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder. |
|
|
|
Post by brentie on Apr 5, 2024 7:07:46 GMT -5
|
|
|
|
Post by uvula on Apr 5, 2024 7:33:38 GMT -5
It's been 2 1/2 pages since anything remotely related to the annual meeting has been posted in this thread lol Looks like the new moderator is not working out. |
|
|
|
Post by Clement on Apr 5, 2024 7:37:30 GMT -5
^ Here's a very interesting paragraph from p 57 of the 10-K: "During the year ended December 31, 2023, we generated $34.1 million of cash from our operating activities, which primarily consisted of $241.3 million of reimbursements from a customer, which is inclusive of approximately $40.0 million of deferred revenue for collaborations and services, partially offset by $84.1 million of cost of goods sold, $46.7 million of selling expenses, $33.4 million of general and administrative expenses, $28.1 million of costs for research and development, $9.6 million of cash paid for interest on the financing liability and $8.7 million of cash paid for interest on notes. " |
|
|
|
Post by Clement on Apr 5, 2024 7:44:08 GMT -5
^ from p 78 of 10-K:
Deferred revenue current $9.1M
Deferred revenue long-term $69.8M
from p 53
Current deferred revenue consists of amounts that are expected to be recognized as revenue
in the next 12 months.
|
|
|
|
Post by BD on Apr 5, 2024 8:46:53 GMT -5
It's been 2 1/2 pages since anything remotely related to the annual meeting has been posted in this thread lol Looks like the new moderator is not working out. Well that came out of left field. This is from a month ago. And if the rest of us don't care about a thread going OT up the wazoo, why would the new guy behave differently? |
|
|
|
Post by cretin11 on Apr 5, 2024 8:53:20 GMT -5
And actually, the thread has mysteriously veered kinda back on topic… maybe a sign the new guy is working out!? 🤣
|
|
|
|
Post by uvula on Apr 5, 2024 8:55:41 GMT -5
Looks like the new moderator is not working out. Well that came out of left field. This is from a month ago. And if the rest of us don't care about a thread going OT up the wazoo, why would the new guy behave differently? First of all, I was just joking around about the new moderator like everyone else was. I didn't realize anyone would take this seriously. Secondly, something weird happened. I just saw your post this morning and didn't realize it was a month old. So I can understand why my comment seemed to come out of left field. Oops. |
|
|
|
Post by cretin11 on Apr 5, 2024 8:57:40 GMT -5
Knowing your usual posting style, my guess was exactly that. Just needed a winky or funny face emoji to make it certain, LOL
|
|
|
|
Post by BD on Apr 5, 2024 9:02:53 GMT -5
Yeah, emojis help. I'm 65, I was diagnosed with ASD about 6 months ago. Reading mnids, especially over the interwebz, is not an Autistic person's strong suit, especially with me.
|
|
|
|
Post by Thundersnow on Apr 5, 2024 12:44:04 GMT -5
The biggest reason Afrezza is not selling is because doctors are not prescribing it. To say persons with diabetes cannot get Afrezza is misleading. I didn't used to be convinced that full-scale multi-arm (expensive and time-consuming) clinical trials were fundamental to marketing Afrezza. Stevil, Matt, Bill McCullough, agedhippie, and others changed my mind. That was a bitter pill to swallow (pun intended) because MannKind simply didn't have the wherewithal to fund it. That is changing. But, its ok not to obsess about Afrezza. MannKind is profitable and has good prospects. Don't believe me? 10 straight days of share price gains starting the day after the last earnings call. Money talks. BS walks. I have to strongly disagree with you. We have key accounts and those doctors are more than willing to prescribe. VDex is more than willing to prescribe. Then what happens? T2s can't get it, insurance will deny them. Ginger V. and the rest of the T1s can't get it because insurance denies coverage. MNKD knows this. That why we have web pages and a help line. Nearly all 1st prescribed PWD gets denied. That is a fact. Even Ginger V. thought she may be taking advantage of the $99 deal which is available after insurance has denied you. What big study do you want? Cipla just ran a big study. Whats the matter with that? We ran the 175. Whats the matter with that? Inhale-3 will fix the label for T1s which the 171 screwed up. The kids study is a big trial and the kids will get approved. Whats the matter with that trial. The problem is once the kids get approved insurance will deny coverage and the moms with have to show another medical condition like needle pheobia. Do you want to run studies to show keeping TITR reduces heart attacks. They have already been done. What did Mike say the Inhale-3 is costing $30M? When are people going to stop blaming the insurance companies. Yes they will DENY on initial submission but the patient and the doctor have to appeal at least 2 or 3x. That's where the problem lies. Doctors don't want to deal with the paperwork and problems in appealing. Both have to be persistent in getting it approved. If you scream loud enough they will approve it. |
|
|
|
Post by sayhey24 on Apr 5, 2024 15:29:10 GMT -5
I have to strongly disagree with you. We have key accounts and those doctors are more than willing to prescribe. VDex is more than willing to prescribe. Then what happens? T2s can't get it, insurance will deny them. Ginger V. and the rest of the T1s can't get it because insurance denies coverage. MNKD knows this. That why we have web pages and a help line. Nearly all 1st prescribed PWD gets denied. That is a fact. Even Ginger V. thought she may be taking advantage of the $99 deal which is available after insurance has denied you. What big study do you want? Cipla just ran a big study. Whats the matter with that? We ran the 175. Whats the matter with that? Inhale-3 will fix the label for T1s which the 171 screwed up. The kids study is a big trial and the kids will get approved. Whats the matter with that trial. The problem is once the kids get approved insurance will deny coverage and the moms with have to show another medical condition like needle pheobia. Do you want to run studies to show keeping TITR reduces heart attacks. They have already been done. What did Mike say the Inhale-3 is costing $30M? When are people going to stop blaming the insurance companies. Yes they will DENY on initial submission but the patient and the doctor have to appeal at least 2 or 3x. That's where the problem lies. Doctors don't want to deal with the paperwork and problems in appealing. Both have to be persistent in getting it approved. If you scream loud enough they will approve it. First off, the issue is not insurance companies. Its cost. Insurance is one way to deal with the cost of afrezza. If afrezza did not require pre auths insurance would not be the issue but no insurance is covering it, straight up. Second, as Ginger Vieira who had to switch insurance companies found out the insurance company denied and then closed the case. Ginger who is one of afrezza's biggest promoters almost gave up herself. If you don't have a medical reason to justify afrezza you are not getting coverage. If you are a T2, you can pretty much forget it until you are insulin dependent. Who should we "blame" for that if not the insurance company? Should we blame the doctor who is now working for a corporation whose time is being tracked by the corporation and are reprimanded for spending too much time on a patient? We could just blame the cost of afrezza. Thats on MNKD. Who do you want to blame; insurance; the lazy doctor; the corporation; or afrezza list price? |
|
